Navigation Links
Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Date:8/28/2007

une 2006, HGS announced that the U.S. government exercised its option under an existing contract to purchase 20,000 doses of ABthrax(TM) (raxibacumab) for the treatment of anthrax disease. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of hematologic and solid malignancies.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. For more information about Albuferon, please visit http://www.hgsi.com/products/albuferon.html. Health professionals or patients interested in Albuferon clinical trials or other studies involving HGS products may inquire via the "Contact Us" section of the Company's web site, http://www.hgsi.com/products/request.html, or by calling (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Apollos human proteins boost stem cell research
5. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
10. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
11. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014   Auxilium Pharmaceuticals ... integrated specialty biopharmaceutical company, today announced that the Company ... on Thursday, August 7, 2014 before the opening of ... a conference call that day at 8:30 a.m. ET ... of 2014. The presentation slides to be used during ...
(Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 /PRNewswire/ ... committee members—who make decisions about which therapies are ... influence formulary placement, according to a new Manhattan ... Makers 2014 . The study finds that P&T ... and pharmacy benefits managers (PBMs) have set a ...
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
(Date:7/31/2014)... 31, 2014 The vineyards are lush, and ... harvest. And, to celebrate, folks are gearing up for the ... 6 and 7, 2014 along the Leelanau Peninsula Wine ... walk or run through the vineyards start-ing at 9:00 a.m. ... A unique course between rows of grapevines offers an experience ...
(Date:7/31/2014)... United Theological Seminary is pleased to welcome ... and Peter J. Bellini. Both began their teaching duties ... a Director of Non-Degree Programs, Mark Abbott, who begins ... Donne, Assistant Professor of New Testament, received a Ph.D. ... Second Temple Judaism, and Greek courses. His research interests ...
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... Guinness International Champions Cup Finals tickets at the Sun ... 2014 Guinness International Champions Cup is now underway. Residents and ... to be able to watch the Guinness International Champions Cup ... The eight teams competing in the tournament have been split ...
(Date:7/31/2014)... Denver, Colorado (PRWEB) July 31, 2014 ... commonly doctors recommend pain killers for this health problem. ... reveals that this new program was created by Peter ... purpose to help sufferers from all over the world ... , If people wish to view pros and ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Andrie, Inc. V. ... , The Michigan Supreme Court has made the determination that ... use tax when the taxpayer was unable to prove during ... purchases. The Court reversed the Court of Appeals decision on ... the use tax exemption for purchases from Michigan sellers. The ...
Breaking Medicine News(10 mins):Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Growing Seminary Welcomes New Faculty 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 3
... another bout of West Nile, a potentially fatal, mosquito-spread infection. ... Control of the Harris county has said that the situation ... is still a large percentage of people in Houston who ... repellants or going out at night in short-sleeve shirts can ...
... out with the report that with UK leading the group, cancer ... use of new drugs. ,The study termed uptake of ... as well as in New Zealand, Poland, Czech Republic and South ... US were leaders in using new cancer drugs. ,The ...
... forty per cent (37 per cent) of British women and a ... unattractive on holiday as a result of excessive exposure to the ... has been conducted to highlight Sun Awareness Week, which kicks off ... over unsightly sunburn has meant that one in three Brits could ...
... eyes, say experts, who advise frequent short breaks every half ... ,Studies have shown that eyestrain and other vision problems ... people using video display terminals at work, said Kerry Beebe, ... ,The most common symptoms are eyestrain, blurred vision, ...
... the brakes on a racing heartbeat. ... the May 11 issue of Circulation Research how an enzyme ... of the heart's "fight-or-flight" reaction to adrenaline. ,A ... setting the pace of the beating heart, triggering its neighbor ...
... who is on a visit to the US, has ... in Hyderabad, promising to provide all necessary infrastructure. ... the signing of an MoU between Stanford University, the ... Research Institute) in California Thursday. ,Under the ...
Cached Medicine News:Health News:Health Authorities Fear West Nile Season Again in US 2Health News:Britains Complacent Attitude To Uptake Of New Cancer Drugs Revealed 2Health News:Burnt Brits Don't Feel Hot 2Health News:Many Hours on Computer may Harm Eyes 2Health News:Slowing the Racing Heart 2Health News:Reddy Asks Stanford University to Open Hyderabad Campus 2
For the quantitative determination of total glucose in serum....
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L). Single vial, dry powder reagent....
Inorganic phosphorus (UV method) reagent is for the quantitative determination of inorganic phosphorus in human serum....
For the quantitative determination of Inorganic Phosphorus in serum. Linearity: 12.0 mg/dl....
Medicine Products: